AGA临床实践更新:青年起病结直肠癌的诊断与管理专家述评
本专家述评旨在帮助临床医生识别18至<50岁青年起病结直肠癌的表现和循证危险因素,并改善管理。内容涵盖流行病学与危险因素、临床表现、诊断与治疗(手术、化疗、免疫肿瘤治疗)、基因检测与胚胎植入前遗传学、生育力保存及监测建议,并给出6条最佳实践建议。
要点
- 无论年龄,出现直肠出血、体重下降、排便习惯改变、腹痛、缺铁性贫血等症状时应进行结直肠诊断评估。
- 应获取患者一级和二级亲属的结直肠癌及其他癌症家族史,并讨论胚系基因检测(靶向基因或多基因panel)。
- 对于散发性青年起病结直肠癌患者,结肠外筛查和结直肠癌监测间隔与老年起病患者相同。
核心结论
- 随着50岁前结直肠癌发病率上升,对出现可能符合结直肠癌症状的患者,无论年龄均应鼓励进行结肠和直肠的诊断性评估。
- 临床医生应获取青年起病结直肠癌患者一级和二级亲属的结直肠癌及其他癌症家族史,并讨论胚系基因检测。
- 临床医生应告知患者在癌症导向治疗(手术、盆腔放疗或化疗)前生育力保存的作用。
- 临床医生应在术前告知患者胚系基因检测和家族癌症panel检测的获益,以指导手术选择。
- 临床医生应考虑利用胚系和体细胞基因检测结果指导化疗策略。
研究设计与样本
- 本专家述评总结了相关科学文献、专家意见声明和当前实践指南。
主要发现
- 青年起病结直肠癌定义为18至<50岁诊断为结直肠癌。
- 述评涵盖流行病学与危险因素、临床表现、诊断与治疗管理(包括结直肠和结肠外手术、化疗和免疫肿瘤治疗)、基因检测及其对胚胎植入前遗传学的潜在影响、生育力保存以及患者和家庭成员的癌症监测建议。
关键数值与推荐
- 最佳实践建议1:对出现可能符合结直肠癌症状(包括但不限于直肠出血、体重下降、排便习惯改变、腹痛、缺铁性贫血)的所有患者,无论年龄,鼓励进行结肠和直肠的诊断性评估。
- 最佳实践建议2:临床医生应获取青年起病结直肠癌患者一级和二级亲属的结直肠癌及其他癌症家族史,并讨论胚系基因检测(基于表型的靶向基因或多基因panel),无论家族史如何。
- 最佳实践建议3:临床医生应在癌症导向治疗(包括手术、盆腔放疗或化疗)前告知患者生育力保存的作用。
- 最佳实践建议4:临床医生应在术前告知患者胚系基因检测和家族癌症panel检测的获益,以指导青年起病结直肠癌患者可选的手术方式。
- 最佳实践建议5:临床医生应考虑利用胚系和体细胞基因检测结果指导化疗策略。
临床怎么用
- 对出现可能符合结直肠癌症状的患者,无论年龄,鼓励进行结肠和直肠的诊断性评估。
- 获取青年起病结直肠癌患者一级和二级亲属的癌症家族史,并讨论胚系基因检测。
- 在癌症导向治疗前告知生育力保存的作用。
- 术前告知胚系基因检测和家族癌症panel检测的获益以指导手术选择,并考虑利用胚系和体细胞基因检测结果指导化疗策略。
- 仅对遗传性或临床诊断遗传性结直肠癌综合征的患者提供综合征特异性筛查,散发性患者的监测间隔与老年起病患者相同。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DESCRIPTION: The objectives of this expert review are: (1) to prepare clinicians to recognize the presentation and evidence-based risk factors for young adult-onset colorectal cancer (CRC), defined as CRC diagnosed in individuals 18 - <50 years of age; (2) to improve management for patients with young onset CRC. This review will focus on the following topics relevant to young adult-onset CRC: epidemiology and risk factors; clinical presentation; diagnostic and therapeutic management including options for colorectal and extra-colonic surgical intervention, chemotherapy and immune-oncology therapies; genetic testing and its potential impact on preimplantation genetics; fertility preservation; and cancer surveillance recommendations for these individuals and their family members. METHODS: The evidence reviewed in this manuscript is a summation of relevant scientific publications, expert opinion statements, and current practice guidelines. BEST PRACTICE ADVICE 1: With the rising incidence of people developing CRC before 50 years of age, diagnostic evaluation of the colon and rectum is encouraged for all patients, irrespective of age, who present with symptoms that may be consistent with CRC, including but not limited to: rectal bleeding, weight loss, change in bowel habit, abdominal pain, iron deficiency anemia. BEST PRACTICE ADVICE 2: Clinicians should obtain family history of colorectal and other cancers in first and second degree relatives of patients with young adult-onset CRC and discuss genetic evaluation with germline genetic testing either in targeted genes based on phenotypic presentation or in multiplex gene panels regardless of family history. BEST PRACTICE ADVICE 3: Clinicians should present the role of fertility preservation prior to cancer-directed therapy including surgery, pelvic radiation, or chemotherapy BEST PRACTICE ADVICE 4: Clinicians should counsel patients on the benefit of germline genetic testing and familial cancer panel testing in the pre-surgical period to inform which surgical options may be available to the patient with young adult-onset CRC BEST PRACTICE ADVICE 5: Clinicians should consider utilizing germline and somatic genetic testing results to inform chemotherapeutic strategies BEST PRACTICE ADVICE 6: Clinicians should offer hereditary CRC syndrome specific screening for CRC and extra-colonic cancers only to young adult-onset CRC patients who have a genetically or clinically diagnosed hereditary CRC syndrome. For patients with sporadic young adult-onset CRC, extra-colonic screening and CRC surveillance intervals are the same as for patients with older adult-onset CRC.
引用
- Boardman LA, Vilar E, You YN, et al. AGA Clinical Practice Update on Young Adult-Onset Colorectal Cancer Diagnosis and Management: Expert Review. Clin Gastroenterol Hepatol. 2020. PMID: 32525015. doi:10.1016/j.cgh.2020.05.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。